Funding · Healthcare & Life Sciences

Cellogen raises Rs 20 crore from Kotak Alts

What they do

Cellogen develops CAR-T cell therapies for cancers using AI-driven platforms

The company raised Rs 20 crore led by Kotak Alternate Asset Managers

It targets lower treatment costs compared to global standards of $500,000

Cellogen Therapeutics has raised Rs 20 crore in funding from investors.
Kotak Alternate Asset Managers led the investment round via its fund.
The company plans to use funds for clinical programs and manufacturing expansion.
Cellogen is preparing for Phase I human clinical trials with CMC Vellore.
The startup aims to advance its gene therapy pipeline significantly this year.
Cellogen holds a patent for its proprietary CAR-T platform technology.
The firm operates a GMP-compliant facility in Noida for manufacturing.
Investors include existing backer Natco Pharma which holds a small stake.

Cellogen targets a price point of $60,000 to $70,000 per treatment.
This cost is significantly lower than global CAR-T therapies costing up to $700,000.
The Indian biotech sector supports over 11,000 startups currently.
Government schemes like Biopharma SHAKTI aid domestic biotech development efforts.

Cellogen develops cell and gene therapies for treating various cancers.
It uses Chimeric Antigen Receptor T-cell (CAR-T) technology for treatments.
The core platform focuses on bispecific dual-antigen CAR-T therapy designs.
These therapies target two cancer markers to reduce patient relapse risks.
Early-stage programs address beta thalassemia and sickle cell disease conditions.
The company utilizes AI-driven platforms for designing new therapeutic agents.
A GMP-compliant facility in Noida handles in-house vector manufacturing.
Cellogen received a patent for its CAR-T platform technology recently.

Cellogen will advance CAR-T clinical programs immediately after funding.
The company plans to expand its gene therapy pipeline offerings.
Regulatory approval is sought for Phase I trials with CMC Vellore.
Manufacturing and regulatory capabilities will be strengthened using new capital.

Kotak Alternate Asset Managers (lead) — Invests via Kotak Life Sciences Fund I.
Natco Pharma (existing) — Acquired a 5.38% stake for slightly over Rs 15 crore previously.

Product: Next-generation CAR-T cell therapies including bispecific dual-antigen CAR-T treatments for cancers and blood disorders
Customers: Blood cancer and blood disorder patients seeking cell therapy treatments
How it makes money: Biotech company developing and commercializing cell and gene therapies
What sets it apart: Developing India's first bispecific CAR-T therapy to make treatments affordable at $60K-$70K versus global pricing of $500K-$700K